Omnicell, Inc.

For Q2 2026, Omnicell reported total revenue of $312 million, product revenue of $175 million, and service revenue of $137 million. Non-GAAP EBITDA was $67 million and non-GAAP EPS was $0.94; GAAP EPS was $0.52 versus $0.12 in the prior-year period. Non-GAAP gross margin was 50%, helped primarily by a $15 million tariff refund, and free cash flow was $56 million. Cash and cash equivalents were $292 million at quarter-end. For Q3 2026, management expects total revenue of $301 million to $307 million, product revenue of $169 million to $172 million, service revenue of $132 million to $135 million, non-GAAP EBITDA of $32 million to $37 million, and non-GAAP EPS of $0.35 to $0.43. For full-year 2026, guidance is product bookings of $425 million to $560 million, total revenue of $1.225 billion to $1.245 billion, product revenue of $690 million to $700 million, service revenue of $535 million to $545 million, year-end ARR of $660 million to $680 million, non-GAAP EBITDA of $175 million to $185 million, and non-GAAP EPS of $2.15 to $2.30.

Randall Lipps said the quarter reflected solid execution, better-than-expected profitability, and a business model that remains resilient as Omnicell pushes toward autonomous medication management. He emphasized that the company is at a “pivot point” as it moves from one generation of technology to the next, and said customer interest is rising around enterprise-wide visibility, interoperability, and workflow transformation. His tone was confident but measured: he repeatedly noted that sales cycles are long and that the refresh cycle is still early.

Baird Radford highlighted the main financial drivers as favorable revenue mix, recurring revenue growth, disciplined cost management, and operating leverage. He also noted a one-time $15 million tariff refund, which lifted Q2 EBITDA and margin, and said memory chip supply pressures will add about $6 million of incremental cost in the second half of 2026, implying a 50 basis point hit to full-year consolidated gross margin and an 80 basis point hit to full-year product gross margin. He pointed to $292 million of cash and $56 million of free cash flow, and said the company is raising full-year profitability guidance even as it widens the bookings range because deal timing is harder to forecast.

Analysts focused on why the full-year bookings range was widened, whether deals were being pushed into 2027, and how much of the pipeline is competitive conversions versus renewals. Management said the lower end mainly reflects timing uncertainty on medium and large deals, not demand deterioration, while the upper end remains intact because they still have line of sight to enough transactions to reach it. On the competitive side, management said it is still early, but engagement is high across both the installed base and competitive accounts; they also said leasing is helping keep conversations open longer, and that OmniSphere monetization details will come later as 2027 guidance nears.